tiprankstipranks
Trending News
More News >

Avalo Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor assumed coverage of Avalo Therapeutics (AVTX) with a Buy rating and $15 price target Avalo is a clinical-stage biotech company developing therapeutics for immunological diseases, the analyst tells investors in a research note. The firm says AVTX-009 is initially being developed to treat hidradenitis suppurativa, which is a large indication with an evolving standard-of-care regimen.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1